Compound News and Research

RSS

Cellectricon, Neusentis to host webinar on phenotypic screening approaches in pain research

Cellectricon, a leading provider of advanced cell-based screening technologies and services, will co-host a webinar with Neusentis, describing the use of native cells to develop an assay with improved physiological relevance over traditional approaches in pain drug discovery research.

From Cellectricon 8 May 2014

Form of baclofen works better at treating narcolepsy

Neuroscientists at SRI International have found that a form of baclofen, a drug used to treat muscle spasticity, works better at treating narcolepsy than the best drug currently available when tested in mice.

8 May 2014

Exelixis presents final Phase 1b data on investigational MEK-BRAF inhibitor combination therapy for metastatic melanoma

Exelixis, Inc. today announced final results from BRIM7, an ongoing phase 1b clinical trial conducted by Roche and Genentech, Exelixis' collaborator and a member of the Roche Group, of the BRAF inhibitor (BRAFi) vemurafenib in combination with the MEK inhibitor cobimetinib in patients with locally advanced/unresectable or metastatic melanoma carrying a BRAFV600 mutation.

7 May 2014

Naurex's two lead antidepressant programs achieve major milestones

Naurex Inc., a privately held biopharmaceutical company leveraging its unique platform to develop novel drugs for diseases of the central nervous system (CNS), today announced that its two lead antidepressant programs achieved major milestones.

6 May 2014

Bayer to purchase consumer care business of Merck & Co, signs co-development deal for sGC modulators

Bayer has agreed to acquire the consumer care business of U.S. pharmaceutical company Merck & Co., Inc., Whitehouse Station, NJ, USA, for a purchase price of USD 14.2 billion (EUR 10.4 billion).

6 May 2014

Compound Formula Rehmannia reduces levodopa-induced dyskinesia in Parkinson's disease

Levodopa is the preferred treatment for Parkinson's disease in the clinic. However, long-term use of levodopa may lead to various motor complications, among which levodopa-induced dyskinesia is the most common, severely affecting patients' quality of life.

6 May 2014

Compounds in soy sauce can be 70 times more potent than first-line HIV drug Tenofovir

For HIV patients being treated with anti-AIDS medications, resistance to drug therapy regimens is commonplace. Often, patients develop resistance to first-line drug therapies, such as Tenofovir, and are forced to adopt more potent medications.

6 May 2014

Teen suicide clusters linked to newspaper reports

Heightened newspaper coverage after a suicide might have a significant impact on the initiation of some teenage suicide clusters, according to new research published in The Lancet Psychiatry journal.

2 May 2014

Scientists receive $2.3M grant to develop new technology to diagnose cancer, rheumatoid arthritis and colitis

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded a $2.3 million grant from the National Institute of General Medical Sciences of the National Institutes of Health to develop new technology to diagnose cancer, rheumatoid arthritis and colitis.

2 May 2014

The rising incidence of multi-drug resistant TB: an interview with Dr Myriam Haxaire-Theeuwes, Compound Development Team Leader, Janssen

MDR-TB is on the rise in a number of regions in the world, because progress towards targets for diagnosis and treatment of multidrug-resistant TB (MDR-TB) is far off-track.

29 Apr 2014

New data from EMD Serono's multiple sclerosis portfolio to be presented at the 66th AAN Annual Meeting

EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that new data from the company's multiple sclerosis (MS) portfolio will be presented at the American Academy of Neurology's 66th Annual Meeting, taking place from April 26 – May 3, in Philadelphia, PA.

26 Apr 2014

Genetically modified E. coli has ability to produce D-ribose

D-ribose is a commercially important sugar used as a sweetener, a nutritional supplement, and as a starting compound for synthesizing riboflavin and several antiviral drugs.

26 Apr 2014

Findings shed light on evolution of mammalian behaviors and their brain mechanisms

A team led by scientists at The Scripps Research Institute has deciphered the surprisingly versatile code by which chemical cues help trigger some of the most basic behaviors in mice.

26 Apr 2014

UB research finds novel compound for treating cocaine addiction

A novel compound that targets an important brain receptor has a dramatic effect against a host of cocaine addiction behaviors, including relapse behavior, a University at Buffalo animal study has found.

25 Apr 2014

NIAMS scientific director to receive 2014 Ross Prize in Molecular Medicine

John J. O'Shea, M.D., scientific director at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), has been named the 2014 recipient of the Ross Prize in Molecular Medicine, conferred by the Feinstein Institute's peer-reviewed, open-access journal Molecular Medicine.

25 Apr 2014

Georgia State researcher receives grant to develop novel therapeutics against RSV infection

Dr. Richard Plemper, a professor in the new Institute for Biomedical Sciences at Georgia State University, has received a five-year, $2.83 million federal grant to develop novel therapeutics against Respiratory Syncytial Virus (RSV) infection.

25 Apr 2014

Tolero Pharmaceuticals' Alvocidib gets Orphan Drug Designation for acute myeloid leukemia treatment

Tolero Pharmaceuticals, Inc., a clinical-stage company developing treatments for serious hematological diseases, today announced that the U.S. Food and Drug Administration has granted Orphan Drug designation for Alvocidib for the treatment of patients with acute myeloid leukemia (AML).

23 Apr 2014

Johns Hopkins scientists find a way to prevent atherosclerosis

Working with mice and rabbits, Johns Hopkins scientists have found a way to block abnormal cholesterol production, transport and breakdown, successfully preventing the development of atherosclerosis, the main cause of heart attacks and strokes and the number-one cause of death among humans. The condition develops when fat builds inside blood vessels over time and renders them stiff, narrowed and hardened, greatly reducing their ability to feed oxygen-rich blood to the heart muscle and the brain.

23 Apr 2014

Climate change can lead to methane formation, cause greenhouse effect

The recent Yokahama IPCC meeting painted a stark warning on the possible effects of gases such as methane - which has a greenhouse effect 32 times that of carbon dioxide.

22 Apr 2014

Scientists examine Gpr109a receptor to find potential treatment for diabetic retinopathy

Like a daily pill to lower cholesterol can reduce heart attack and stroke risk, an easy-to-use agent that reduces eye inflammation could help save the vision of diabetics, scientists say.

22 Apr 2014

Compound News and Research

Cellectricon, Neusentis to host webinar on phenotypic screening approaches in pain research

Form of baclofen works better at treating narcolepsy

Exelixis presents final Phase 1b data on investigational MEK-BRAF inhibitor combination therapy for metastatic melanoma

Naurex's two lead antidepressant programs achieve major milestones

Bayer to purchase consumer care business of Merck & Co, signs co-development deal for sGC modulators

Compound Formula Rehmannia reduces levodopa-induced dyskinesia in Parkinson's disease

Compounds in soy sauce can be 70 times more potent than first-line HIV drug Tenofovir

Teen suicide clusters linked to newspaper reports

Scientists receive $2.3M grant to develop new technology to diagnose cancer, rheumatoid arthritis and colitis

The rising incidence of multi-drug resistant TB: an interview with Dr Myriam Haxaire-Theeuwes, Compound Development Team Leader, Janssen

New data from EMD Serono's multiple sclerosis portfolio to be presented at the 66th AAN Annual Meeting

Genetically modified E. coli has ability to produce D-ribose

Findings shed light on evolution of mammalian behaviors and their brain mechanisms

UB research finds novel compound for treating cocaine addiction

NIAMS scientific director to receive 2014 Ross Prize in Molecular Medicine

Georgia State researcher receives grant to develop novel therapeutics against RSV infection

Tolero Pharmaceuticals' Alvocidib gets Orphan Drug Designation for acute myeloid leukemia treatment

Johns Hopkins scientists find a way to prevent atherosclerosis

Climate change can lead to methane formation, cause greenhouse effect

Scientists examine Gpr109a receptor to find potential treatment for diabetic retinopathy

Enhancing confidence in chemical ionization spectrometry data eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News